Neural Therapy in Cesareans

Launched by HASEKI TRAINING AND RESEARCH HOSPITAL · May 22, 2025

Keywords

ClinConnect Summary

This clinical trial, titled "Neural Therapy in Cesareans," is exploring new ways to manage pain after a cesarean section (C-section). Currently, patients often receive medications like opioids and anti-inflammatory drugs to help with pain, but these can sometimes be ineffective or cause unwanted side effects. The trial aims to compare traditional pain relief methods with new techniques that involve applying local anesthesia directly to the skin around the surgical site. The goal is to find the best approach to help women recover more comfortably after their C-sections, improving their overall satisfaction and quality of life.

To participate in this trial, women must be pregnant and either close to their due date (over 37 weeks) or at a preterm stage (between 28-34 weeks). They should be having a C-section with general anesthesia, and there are specific criteria regarding health and pregnancy conditions that must be met. Participants can expect to receive either the standard pain relief methods or the new local anesthesia techniques during their recovery. Importantly, this research is not yet recruiting participants, but it represents a promising step toward better pain management for women undergoing cesarean deliveries.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Healthy pregnancy,
• • Term (\>37 weeks) and preterm (28-34 weeks) pregnancy,
• • Cases that received general anesthesia for cesarean section,
• • Cases with and without labor,
• • Cases with and without obesity,
• • Cases that had their first or second cesarean section
• Exclusion Criteria:
• • Pregnant women under 19 years of age,
• • Those with a history of allergic reactions to analgesics to be used,
• • Stillbirth,
• • Surgical complications during C/S and placement of an abdominal drain,
• • No head or breech presentation during C/S,
• • Occiput posterior presentation during C/S,
• • Anhydramnios and polyhydramnios,
• • Allergic reactions to the drugs used in the study, alcohol dependence, drug and substance dependence, chronic pain syndrome, neuropathic pain disorder history,
• • History of clinically significant cardiovascular, pulmonary, hepatic, renal, neurological, psychiatric, metabolic disease.